SCHEMBL4197779

SCHEMBL4197779

CCCC1C(C)=C(C)C(C)=C1C

nearest known ligand 0.34

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7648197 0.82 ALDH1A1 (0.40) ALDH1A1LMNATP53HPGDTSHR
SCHEMBL8164102 0.73
SCHEMBL13049890 0.66 LMNA (0.36) ALDH1A1LMNATSHRHSD17B10
SCHEMBL22411242 0.61
SCHEMBL8419246 0.61
SCHEMBL22783953 0.61
SCHEMBL22411236 0.61
SCHEMBL22411237 0.60
SCHEMBL8164372 0.59
SCHEMBL27446122 0.59

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9408853-B2 Iridium/rhodium anti-cancer compounds UNIVERSITY OF WARWICK (GB) 2016-08-09 US disclosed
EP-2734554-A1 METHOD FOR PREPARING DIALKYL MAGNESIUM COMPOUNDS BY ETHYLENE POLYMERISATION AND USES THEREOF Universite De Lille 1 Sciences Et Technologies (FR) 2014-05-28 EP disclosed
EP-2575801-A1 NOVEL IRIDIUM/RHODIUM ANTI-CANCER COMPOUNDS University of Warwick (GB) 2013-04-10 EP disclosed
US-20130065864-A1 NOVEL IRIDIUM/RHODIUM ANTI-CANCER COMPOUNDS UNIVERSITY OF WARWICK (GB) 2013-03-14 US disclosed
WO-2013014383-A1 METHOD FOR PREPARING DIALKYL MAGNESIUM COMPOUNDS BY ETHYLENE POLYMERISATION AND USES THEREOF UNIVERSITE DE LILLE 1 SCIENCES ET TECHNOLOGIES (FR) 2013-01-31 WO disclosed
US-8293327-B2 Process for forming the strontium-containing thin film KABUSHIKIKAISHA KOJUNDOKAGAKU KENKYUSHO (JP) 2012-10-23 US disclosed
WO-2011148124-A1 NOVEL IRIDIUM/RHODIUM ANTI-CANCER COMPOUNDS UNIVERSITY OF WARWICK (GB) 2011-12-01 WO disclosed
US-7635441-B2 Raw material for forming a strontium-containing thin film and process for preparing the raw material KABUSHIKIKAISHA KOJUNDOKAGAKU KENKYUSHO (JP) 2009-12-22 US disclosed
US-20090001618-A1 RAW MATERIAL FOR FORMING A STRONTIUM-CONTAINING THIN FILM AND PROCESS FOR PREPARING THE RAW MATERIAL KABUSHIKIKAISHA KOJUNDOKAGAKU KENKYUSHO (JP) 2009-01-01 US disclosed
US-20090004383-A1 PROCESS FOR FORMING THE STRONTIUM-CONTAINING THIN FILM KABUSHIKIKAISHA KOJUNDOKAGAKU KENKYUSHO (JP) 2009-01-01 US disclosed
CN-1136548-A Process for preparation of cyclopentadinyl compounds and compounds obtained therefrom MONTELL TECHNOLOGY COMPANY BV (NL) 1996-11-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065864-A1 NOVEL IRIDIUM/RHODIUM ANTI-CANCER COMPOUNDS RBBP5, ANXA5, RAB35 ALDH1A1 2305/4885LMNA 4198/4885TP53 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.